Efficacy and safety of antiplatelet drugs in patients with chronic kidney disease

The risks and benefits of antiplatelet treatment may be different in patients with chronic kidney disease, in whom tendency to thrombosis and bleeding hazards might be increased. Chronic kidney disease is also associated with poor response to antiplatelet therapy, and this represents a potentially important clinical problem in the setting of percutaneous coronary intervention and acute coronary syndrome. The use of new, potent P2Y12 inhibitors appears promising, although special consideration should be given to possible bleeding events. This review evaluates the benefits and harms of antiplatelet drugs in patients with chronic kidney disease.